Technical Analysis for CBAY - CymaBay Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 12.9 0.00% 0.00
CBAY closed unchanged on Friday, May 24, 2019, on 1.85 times normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CBAY trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish 4.88%

Older signals for CBAY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Medicine Chemistry Disorders Health Care Therapeutic Products Regulus Therapeutics Metabolic Diseases Ii Diabetes Gout
Is CBAY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.0
52 Week Low 6.31
Average Volume 722,795
200-Day Moving Average 11.0188
50-Day Moving Average 12.829
20-Day Moving Average 12.774
10-Day Moving Average 12.696
Average True Range 0.6164
ADX 12.13
+DI 18.3483
-DI 22.6931
Chandelier Exit (Long, 3 ATRs ) 11.7008
Chandelier Exit (Short, 3 ATRs ) 13.5992
Upper Bollinger Band 13.3547
Lower Bollinger Band 12.1933
Percent B (%b) 0.61
BandWidth 9.091905
MACD Line -0.0011
MACD Signal Line 0.0078
MACD Histogram -0.0089
Fundamentals Value
Market Cap 564.45 Million
Num Shares 43.8 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -12.06
Price-to-Sales 82.44
Price-to-Book 122.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.55
Resistance 3 (R3) 13.53 13.29 13.44
Resistance 2 (R2) 13.29 13.13 13.30 13.40
Resistance 1 (R1) 13.10 13.03 12.98 13.12 13.37
Pivot Point 12.86 12.86 12.81 12.87 12.86
Support 1 (S1) 12.67 12.70 12.55 12.69 12.43
Support 2 (S2) 12.43 12.60 12.44 12.40
Support 3 (S3) 12.24 12.43 12.36
Support 4 (S4) 12.26